Table 3.

Adverse events through week 52

	Golimumab-IV	Infliximab
Patients, N	685	585
Mean follow-up, weeks	41.3	41.3
Patients with ≥ 1 AE	348 (50.8)	356 (60.9)
Patients with ≥ 1 serious AE	66 (9.6)	60 (10.3)
Patients with ≥ 1 infection or infestation	156 (22.8)	155 (26.5)
Patients with ≥ 1 opportunistic infection	10 (1.5)	9 (1.5)
Patients with ≥ 1 serious infection	21 (3.1)	20 (3.4)
Patients with ≥ 1 malignancy	13 (1.9)	10 (1.7)
Latent tuberculosis	0	1 (0.2)
Most common AEs (occurring in ≥ 5% of either regimen)
Nausea	20 (2.9)	38 (6.5)
Worsening of rheumatoid arthritis	23 (3.4)	32 (5.5)
Upper respiratory tract infection	28 (4.1)	30 (5.1)
Pruritus	10 (1.5)	30 (5.1)

Data presented as n (%) unless otherwise noted

AE adverse event, IV intravenous